202 related articles for article (PubMed ID: 36302916)
21. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Sharp A; Welti J; Blagg J; de Bono JS
Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
Li H; Hassona MD; Lack NA; Axerio-Cilies P; Leblanc E; Tavassoli P; Kanaan N; Frewin K; Singh K; Adomat H; Böhm KJ; Prinz H; Guns ET; Rennie PS; Cherkasov A
Mol Cancer Ther; 2013 Nov; 12(11):2425-35. PubMed ID: 23939374
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
24. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
25. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
Sadar MD
Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
[TBL] [Abstract][Full Text] [Related]
26. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
27. Regulation of Androgen Receptor Activity by Transient Interactions of Its Transactivation Domain with General Transcription Regulators.
De Mol E; Szulc E; Di Sanza C; Martínez-Cristóbal P; Bertoncini CW; Fenwick RB; Frigolé-Vivas M; Masín M; Hunter I; Buzón V; Brun-Heath I; García J; De Fabritiis G; Estébanez-Perpiñá E; McEwan IJ; Nebreda ÁR; Salvatella X
Structure; 2018 Jan; 26(1):145-152.e3. PubMed ID: 29225078
[TBL] [Abstract][Full Text] [Related]
28. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
[TBL] [Abstract][Full Text] [Related]
29. [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].
Hupe MC; Offermann A; Perabo F; Chandhasin C; Perner S; Merseburger AS; Cronauer MV
Urologe A; 2018 Feb; 57(2):148-154. PubMed ID: 29147733
[TBL] [Abstract][Full Text] [Related]
30. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
31. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.
Maurice-Dror C; Le Moigne R; Vaishampayan U; Montgomery RB; Gordon MS; Hong NH; DiMascio L; Perabo F; Chi KN
Invest New Drugs; 2022 Apr; 40(2):322-329. PubMed ID: 34843005
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878
[TBL] [Abstract][Full Text] [Related]
33. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
[No Abstract] [Full Text] [Related]
34. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
35. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
Elife; 2023 Jan; 12():. PubMed ID: 36656639
[TBL] [Abstract][Full Text] [Related]
36. Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resistance.
Nicolescu RCB; Maylin ZR; Pérez-Areales FJ; Iegre J; Pandha HS; Asim M; Spring DR
ChemMedChem; 2023 Jan; 18(2):e202200548. PubMed ID: 36300876
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
38. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
Lv S; Song Q; Chen G; Cheng E; Chen W; Cole R; Wu Z; Pascal LE; Wang K; Wipf P; Nelson JB; Wei Q; Huang W; Wang Z
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332287
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Strategies to Target the Androgen Receptor.
Xiang W; Wang S
J Med Chem; 2022 Jul; 65(13):8772-8797. PubMed ID: 35786895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]